DelveInsight’s report “Hypoparathyroidism – Market Insights, Epidemiology, and Market Forecast-2030” provides an in-depth understanding of Hypoparathyroidism, historical and forecasted epidemiology, as well as Hypoparathyroidism market patterns in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Some of the Key Highlights from the Hypoparathyroidism Market Report
According to the report titled “Epidemiology and Diagnosis of Hypoparathyroidism” (2016), the incidence of Hypoparathyroidism in the United States is reported to be 37 per 100 000 person-years.
According to Zanocco et al. (2017), Primary Hyperparathyroidism (PHPT) affects 0.2 percent to 0.5 percent of the population in the United States.
Hypoparathyroidism Pipeline therapies include PTH(1-34) (Entera Bio), TransCon PTH (Ascendis Pharma) and others.
Major players involved in the Hypoparathyroidism market are Entera Bio, Ascendis Pharma, among others.
The rise in Hypoparathyroidism market size is a direct result of the growing incidence of Hypoparathyroidism.
To learn more request sample @ Hypoparathyroidism Market Outlook
The Hypoparathyroidism market report includes emerging clinical trends, new drugs, market share of individual therapies, and current and forecasted Hypoparathyroidism market sizes in the 7MM (the United States, the EU5, Germany, Italy, Spain, and France), as well as Japan.
Hypoparathyroidism: Disease Overview
Hypoparathyroidism is a rare endocrine condition characterised by low calcium and high phosphate levels combined with a low or abnormally normal PTH level. The United States and the European Commission have designated hypoparathyroidism as an orphan condition.
Hypoparathyroidism causes a wide variety of physical, behavioural, cognitive, and emotional effects in those who have it. They also experience debilitating symptoms, which can have a significant effect on quality of life and overall productivity, including the ability to work and perform household tasks.
Hypoparathyroidism Epidemiology Segmentation
Hypoparathyroidism Total Prevalent Population
Hypoparathyroidism Type-Specific Population
Hypoparathyroidism Gender-Specific Population
Hypoparathyroidism Diagnosed and Treatable Population
Hypoparathyroidism Treatment landscape
The aim of Hypoparathyroidism treatment is to correct hypocalcemia and hyperphosphatemia, as well as to alleviate symptoms and avoid chronic complications.
Standard treatment includes Calcium supplements and activated Vitamin D, namely Calcitriol or Alfacalcidol. Vitamin D2 (Ergocalciferol) or Vitamin D3 (Cholecalciferol) supplements, Magnesium, and Thiazide diuretics.
The current clinical environment of Hypoparathyroidism in the United States will be guided by increased knowledge and growth programmes. Hypoparathyroidism is expected to grow in popularity by 2030. The introduction of the most awaited therapies like PTH (1-34) and TransCon PTH, which are seen as a challenge to the existing market, is the primary cause of market growth.
For more information visit @ Hypoparathyroidism Treatment Market
Hypoparathyroidism Pipeline Therapies and Key Companies
PTH (1-34): Entera Bio
TransCon PTH: Ascendis Pharma
Table of Contents
Executive Summary of Hypoparathyroidism
Hypoparathyroidism Market Share at a glance
Hypoparathyroidism: Disease Background and Overview
Hypoparathyroidism Epidemiology and Patient Population
Country Wise: Epidemiology of Hypoparathyroidism
Hypoparathyroidism Current Treatment and Medical Practices
Hypoparathyroidism: Marketed Drugs
Current Unmet Needs of Hypoparathyroidism
Hypoparathyroidism Emerging Therapeutics
Hypoparathyroidism– The US Market Analysis
Region-Wise Market size of Hypoparathyroidism
Hypoparathyroidism: Market Barriers
Hypoparathyroidism Market Access and Reimbursement
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts
Get comprehensive historical and forecast analysis of Hypogonadism Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Endo International Plc., AbbVie Inc., Pfizer Inc., Allergan Plc., among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States